WVE insider buying and SEC filings, explained
Wave Life Sciences Ltd. · CIK 1631574
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$82.6M
Insiders who bought
2
Sold (not marked 10b5-1)
$258K
Planned sales (10b5-1)
$15.9M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Aug 12, 2026 | Planned (10b5-1) | Adrian Rawcliffe (Director) sold 12,700 shares at about $5.29 ($67K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Aug 13, 2026 |
| Aug 11, 2026 | Planned (10b5-1) | Heidi L Wagner (Director) sold 7,000 shares at $6.01 ($42K), marked as a 10b5-1 plan trade. Holdings down 13% to 44,930 shares. | SEC filing Filed Aug 13, 2026 |
| Aug 11, 2026 | Planned (10b5-1) | Ken Takanashi (Director) sold 3,864 shares at about $6.01 ($23K), marked as a 10b5-1 plan trade. Holdings down 16% to 20,079 shares. | SEC filing Filed Aug 13, 2026 |
| Aug 11, 2026 | Planned (10b5-1) | Aik Na Tan (Director) sold 432 shares at $6.01 ($3K), marked as a 10b5-1 plan trade. Holdings down 2% to 24,968 shares. | SEC filing Filed Aug 13, 2026 |
| Mar 26–30, 2026 | Purchase (code P) | Peter Kolchinsky (Director and 10% owner) bought 8,772,496 shares indirectly between Mar 26 and Mar 30 at about $6.23 ($54.6M), reported as a purchase (code P). Indirect holdings up 48% to 26,975,505 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 3 other reporting owners. | SEC filing Filed Mar 30, 2026 |
| Feb 26, 2026 | Planned (10b5-1) | Chris Francis (Officer) sold 33,194 shares at about $15.05 ($500K), marked as a 10b5-1 plan trade. Holdings down 35% to 61,867 shares. | SEC filing Filed Feb 27, 2026 |
| Feb 9, 2026 | Sale | Kyle Moran (CFO) sold 3,588 shares at $13.45 ($48K). Holdings down 3% to 134,385 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 11, 2026 |
| Feb 9, 2026 | Sale | Paul Bolno (CEO and Director) sold 10,480 shares at $13.45 ($141K). Holdings down 4% to 275,520 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 11, 2026 |
| Feb 9, 2026 | Sale | Chris Francis (Officer) sold 1,883 shares at $13.45 ($25K). Holdings down 3% to 61,867 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 11, 2026 |
| Feb 9, 2026 | Sale | Chandra Vargeese (Chief Technology Officer) sold 3,228 shares at $13.45 ($43K). Holdings down 1% to 408,246 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 11, 2026 |
| Jan 2, 2026 | Planned (10b5-1) | Chris Francis (Officer) sold 9,375 shares at about $16.03 ($150K), marked as a 10b5-1 plan trade. Holdings down 27% to 25,000 shares. | SEC filing Filed Jan 6, 2026 |
| Dec 11, 2025 | Purchase (code P) | GSK plc (10% owner) bought 1,470,000 shares indirectly at $19.00 ($27.9M), reported as a purchase (code P). Indirect holdings up 9% to 18,245,691 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 15, 2025 |
| Dec 8, 2025 | Planned (10b5-1) | Adrian Rawcliffe (Director) sold 42,000 shares at $15.00 ($630K), marked as a 10b5-1 plan trade. Holdings down 77% to 12,700 shares. | SEC filing Filed Dec 10, 2025 |
| Dec 8, 2025 | Planned (10b5-1) | Heidi L Wagner (Director) sold 14,000 shares at about $13.50 ($189K), marked as a 10b5-1 plan trade. Holdings down 24% to 44,930 shares. | SEC filing Filed Dec 10, 2025 |
| Dec 8, 2025 | Planned (10b5-1) | Christian O. Henry (Director) sold 93,445 shares at about $14.65 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 88% to 12,700 shares. | SEC filing Filed Dec 10, 2025 |
| Dec 8, 2025 | Planned (10b5-1) | Aik Na Tan (Director) sold 134,218 shares at about $13.58 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 84% to 25,400 shares. | SEC filing Filed Dec 10, 2025 |
| Dec 8, 2025 | Planned (10b5-1) | Gregory L. Verdine (Director) sold 20,000 shares at about $13.47 ($269K), marked as a 10b5-1 plan trade. Holdings down 7% to 275,217 shares. | SEC filing Filed Dec 10, 2025 |
| Dec 8, 2025 | Planned (10b5-1) | Chris Francis (Officer) sold 441,031 shares at about $14.58 ($6.4M), marked as a 10b5-1 plan trade. Holdings down 95% to 25,000 shares. | SEC filing Filed Dec 10, 2025 |
| Dec 8–9, 2025 | Planned (10b5-1) | Kyle Moran (CFO) sold 260,036 shares between Dec 8, 2025 and Dec 9, 2025 at about $15.78 ($4.1M), marked as a 10b5-1 plan trade. Holdings down 74% to 90,365 shares. | SEC filing Filed Dec 10, 2025 |
| Dec 8, 2025 | Planned (10b5-1) | Mark Corrigan (Director) sold 16,115 shares at about $13.49 ($217K), marked as a 10b5-1 plan trade. Holdings down 36% to 28,815 shares. | SEC filing Filed Dec 10, 2025 |
| Nov 13, 2025 | Purchase (code P) | Peter Kolchinsky (Director and 10% owner) bought 1,000 shares indirectly at about $6.69 ($7K), reported as a purchase (code P). Indirect holdings up <1% to 18,203,009 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 3 other reporting owners. | SEC filing Filed Nov 14, 2025 |
| Nov 13, 2025 | Planned (10b5-1) | Adrian Rawcliffe (Director) sold 16,115 shares at about $6.79 ($109K), marked as a 10b5-1 plan trade. Holdings down 56% to 12,700 shares. | SEC filing Filed Nov 14, 2025 |
22 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow WVE in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.